<DOC>
	<DOCNO>NCT01794455</DOCNO>
	<brief_summary>This pilot proposal test hypothesis alter cerebral vessel reactivity cerebral hypoperfusion ( decreased blood flow brain ) core mechanism underlie relationship vascular disease depression old adult . The long-term objective line research : A ) determine relationship vascular reactivity , cerebral hypoperfusion persistence late-life depression B ) determine improve cerebral perfusion angiotensin receptor blocker ( ARBs ) improve depression outcome .</brief_summary>
	<brief_title>Effects Cerebral Hypoperfusion Its Reversal Late-Life Depression</brief_title>
	<detailed_description>This study examine magnetic resonance imaging ( MRI ) measure cerebral perfusion relate antidepressant response . There two phase study . In first phase , examine cerebral perfusion relate response sertraline , commonly use antidepressant . In second phase , examine individual respond sertraline selective serotonin reuptake inhibitor ( SSRI ) . We examine candesartan , ARB , improve depression improve cerebral perfusion . After provide informed consent , participant undergo medical psychiatric screening . Participants determine eligible screen proceed baseline evaluation , include brief cognitive neuropsychological test MRI . Participants begin open-label sertraline eight week ( baseline week 8 ) . Dosing begin 50mg daily , base response tolerability , increase FDA approve maximum dose 200mg daily . After eight week , participant re-evaluated complete another MRI . Those respond sertraline experience remission depression end study participation . Those experience remission continue phase 2 open-label candesartan arm . The candesartan arm last 12 week ( week 8 week 20 ) . Dosing begin 4mg daily increase maximum dose 32mg , base tolerability response . Participants monitor closely , antihypertensive medication adjust avoid low blood pressure . At end 12-week trial , participant complete MRI neuropsychological testing . Their study participation end .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>1 . Age 60 year old 2 . Diagnosis Major Depressive Disorder , single recurrent episode , without psychotic feature Diagnostic Statistical Manual IV Text Revision ( DSMIVTR ) criteria 3 . Presence hypertension ( define systolic &gt; 140 diastolic &gt; 90 currently receive antihypertensive therapy ) 4 . Minimum depression severity ≥ 15 MontgomeryAsberg Depression Rating Scale ( MADRS ) 5 . Cognitively intact mild cognitive deficit , minimum score ≥ 23 Montreal Cognitive Assessment ( MoCA ) . 1 . Other psychiatric Axis I disorder 2 . Acute suicidality 3 . Electroconvulsive therapy last 6 month 4 . Primary neurological disorder , include dementia stroke 5 . Significant cardiovascular disease , specifically diagnosis congestive heart failure , know bilateral renal artery stenosis , symptomatic hypotension , critical aortic mitral stenosis 6 . Myocardial infarction openheart surgery last 6 week 7 . Serum creatinine ≥ 265 micromol /L 8 . Serum potassium ≥ 5.5 mmol/L 9 . MRI contraindication 10 . Known allergy sertraline candesartan specifically know allergy SSRIs ARBs . 11 . History prolong ( &gt; 3 week ) selfdescribed severe discontinuation syndrome past stop antidepressant . 12 . Current use angiotensin receptor blocker 13 . Current plan psychotherapy 14 . Need continuous oxygen use medical disorder hypercapnia challenge would contraindicate put subject increase risk . This would include acute respiratory disease , chronic angina , unstable cardiac condition .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Geriatrics</keyword>
	<keyword>Hypertension</keyword>
</DOC>